Data Readout

Cloudbreak's CBT-001 nears Phase 3 pterygium data after Phase 2 hit both endpoints

The topical multi-kinase inhibitor reduced pterygium vascularity and lesion size versus vehicle in Phase 2, setting the bar its 660-patient Phase 3 must replicate in a disease with no approved disease-modifying drug.

By AppliedXLJuly 14, 2026Trial NCT05456425

Executive Summary

Cloudbreak Pharma is approaching a Phase 3 readout for its lead eye-drop candidate in pterygium, a disease that currently has no approved drug that modifies its underlying course.
The company's own earlier-stage trial of the same drug already cleared the bar the Phase 3 will re-test, reducing both the vascularity and the physical size of the lesion against an inactive comparator.
The sponsor has repeated the same third-quarter readout guidance three times since April, even as the trial's own registry completion date has slipped twice and now sits a year beyond that guided window.
No other program shares this drug's multi-kinase mechanism in pterygium, and the closest competing candidates in the disease work through unrelated pathways, leaving CBT-001 to define its own precedent rather than beat a rival's number.

The catalyst

Cloudbreak Pharma Inc. has told investors three times since April 2026 that topline Phase 3 data for CBT-001 in pterygium are coming in the third quarter of the year, with the guidance repeated on April 9, April 22, and June 4 without change. The trial behind that guidance, NCT05456425, is a randomized, Phase 3 study testing CBT-001 eye drops against a vehicle comparator across two arms, with pterygium length and conjunctival hyperemia (eye redness from surface blood vessels) as co-primary endpoints. The study enrolled 660 patients across sites in the United States, China, India, Australia, and New Zealand and is now Active, not recruiting, meaning enrollment has closed and the trial is following patients to the readout. Cloudbreak+1

Probability of Success

Endpoint Met91%

Completes67%

Clinical Significance38%

Regulatory82%

The Phase 2 precedent

CBT-001 has produced a positive readout on the same disease before. In a completed 75-patient Phase 2 trial (NCT03049852), the drug reduced pterygial vascularity versus vehicle at four weeks (p<0.001) and reduced lesion size versus vehicle (p<0.014), with safety described as favorable. That result met the study's primary endpoint and gives the Phase 3 trial a specific band to reproduce at nearly nine times the patient count, rather than a novel hypothesis being tested for the first time. Cloudbreak's chief medical officer, Abu Abraham, MD, called the coming data "a critical data readout for our lead Phase 3 asset" when the company relaunched its investor-facing website in April. NCT05456425+1

The timing question

The registry tells a more complicated timing story than the press releases do. NCT05456425's primary completion date moved from December 2024 to December 2025 in March 2024, then from December 2025 to December 2026 in September 2025, a cumulative 730-day delay recorded in the trial's own change history. That September 2025 update also raised the enrollment target from 600 to 660 patients, a change the trial's own operational-risk model flags as within the routine band, not an unusual shift. The trial's overall completion date on file is December 2027, a year beyond even the revised primary completion date, which leaves room for the topline readout guided to Q3 2026 to land as an interim or primary-endpoint cut of the data rather than the trial's full close-out. NCT05456425

The competitive frame

Pterygium has no FDA-approved disease-modifying drug, and most patients are managed with symptomatic measures such as artificial tears or off-label NSAIDs and corticosteroids, with surgery reserved for more severe cases. The named trials active in the indication, including studies of dexamethasone, bromfenac, and a fibrin glue, work through corticosteroid, COX, and mechanical mechanisms distinct from CBT-001's multi-kinase inhibition, so none stands as a direct comparator on mechanism. That leaves CBT-001's own Phase 2 result as the nearest precedent the Phase 3 trial will be measured against, rather than a rival drug's data. Cloudbreak+1

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.